Portfolio News

16Sep

Premama® Achieves 700% Record Growth, Continuing to Fuel the Emerging Maternity Wellness Category

Premama®, the first nationwide line of natural powdered drink mixes and soft chews to support complete maternity wellness from preconception through pregnancy and beyond, today announced a record retail expansion, experiencing rapid growth from 1,100 to 7,700 retail distribution points since April 2015 and a significant 360% growth in sales from August 2015 to August 2016. Spearheading maternity wellness as a retail category, Premama has pioneered industry awareness and consumer demand with products for the entire maternity journey.
Portfolio News
Read more...
14Sep

Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium

Siamab Therapeutics, Inc., a biotechnology company developing novel cancer immunotherapies, today announced new pre-clinical data that showed its novel ST1 antibody drug conjugates (ADCs) target chemoresistant ovarian cancer cells and demonstrate strong efficacy in ovarian cancer models. These data were presented at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium 2016 in Seattle, Wash., on Monday, Sept. 12, 2016.
Portfolio News
Read more...
07Sep

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline

llergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead development...
Portfolio News
Read more...